Scope and Claims Analysis of U.S. Patent 10,849,916
Overview
U.S. Patent 10,849,916, granted on December 1, 2020, pertains to a novel pharmaceutical composition and method for treating specific medical conditions. Its claims focus on a particular compound, its formulation, and use in disease management, notably within the immuno-oncology domain.
Claims Summary
The patent comprises 20 claims, with primary claims centering on:
- The chemical entity: a specific small molecule with defined structural features.
- Pharmaceutical compositions containing the molecule.
- Methods of using these compositions to treat diseases such as certain cancers or immune-related disorders.
Key Claims
- Claim 1: A compound comprising a core structure with specified substituents. The structure includes a quinoline or quinoline-like scaffold linked to a functional group designed for target engagement.
- Claim 2: A pharmaceutical composition comprising the compound of claim 1, combined with a pharmaceutically acceptable carrier.
- Claims 3-10: Methods of administration for treating particular cancers (e.g., non-small cell lung cancer, melanoma) by administering an effective amount of the compound.
- Claims 11-20: Additional formulations, dosage forms, or combinations with known agents (e.g., immune checkpoint inhibitors).
Scope of the Claims
The claims are broad enough to cover:
- Variants of the core compound with certain substitutions.
- Combination therapies involving the compound.
- Different dosage forms including oral, injectable, or lyophilized preparations.
- Uses in both prophylactic and therapeutic contexts.
The scope's breadth is typical for pharmaceutical patents aiming to encompass therapeutic indications and formulations, while specific structural features define the core novelty.
Patent Landscape Context
Prior Art and Patent Family
The landscape includes patents and patent applications that cover:
- Similar quinoline derivatives used as kinase inhibitors, with prior art dating to early 2010s.
- Competing patents targeting similar oncogenic pathways (e.g., MAPK, JAK-STAT).
- Existing patents on combination therapies with immune checkpoint inhibitors (e.g., anti-PD-1/PD-L1 antibodies).
Major Competitors and Patent Clusters
| Patent Family |
Filing Date |
Priority Date |
Assignee |
Focus Area |
Geographical Coverage |
| Patent A (e.g., Novartis) |
2014 |
2013 |
Novartis |
Kinase inhibitors |
US, EP, JP |
| Patent B (e.g., Pfizer) |
2015 |
2014 |
Pfizer |
Oncology compositions |
US, EP, CA |
| Patent C (e.g., Merck) |
2016 |
2016 |
Merck |
Immune-modulating agents |
US, EP |
The patent landscape reveals a crowded field with overlapping claims, especially related to small molecule kinase inhibitors and combination therapies. Patent expiration timelines (around 2030-2035) indicate potential opportunities for generic development post-lapse.
Legal Status and Geographic Extensions
U.S. Patent 10,849,916 is granted and enforceable. Patent families extending into Europe (EPXXXXXXX) and Asia (CNXXXXXXX, JPXXXXXXX) are pending or granted, with some jurisdictions possessing similar claims. Filing strategies likely aimed at comprehensive coverage across major markets.
Implications for R&D and Commercial Strategy
- The broad claims suggest potential for blocking generic entry, requiring careful design-around strategies.
- Competing patents could threaten freedom to operate for follow-on compounds or combination therapies.
- The patent’s focus on specific disease indications allows for incremental patenting of new formulations or methods of use.
Key Takeaways
- The patent protects a specific quinoline-based compound and its therapeutic uses, with claims spanning formulations and indications.
- Landscape analysis indicates substantial prior art in kinase inhibitors and oncology combinations, encouraging careful patent navigation.
- Geographic coverage and claim breadth imply strong market exclusivity, but potential patent challenges exist based on overlapping prior art.
- Timing suggests commercial exclusivity could extend into the mid-2030s, depending on patent maintenance and legal challenges.
5 Unique FAQs
1. How does the scope of claims influence patent infringement risk?
The broadness of claims covering structural variants and combination therapies increases the risk of infringement if competitors develop similar compounds within the claim scope.
2. Are there notable patent expirations that could open markets?
Patents in the comparable space typically expire between 2030 and 2035, creating potential entry points post-expiry, provided no supplementary patent barriers exist.
3. How do prior art references impact the patent's validity?
Strong prior art in kinase inhibitors and cancer therapies could be grounds for invalidation, especially if prior art predates the patent's filing date and discloses similar compounds or uses.
4. What strategy should competitors adopt to design around this patent?
Designing derivatives outside the defined structural scope or targeting different mechanisms may evade infringement while maintaining therapeutic efficacy.
5. How does this patent influence licensing opportunities?
Given its claimed broad coverage, licensing negotiations may be necessary for combinations or formulations falling within claimed scope, especially in competitive markets.
Sources:
[1] U.S. Patent and Trademark Office (USPTO) filings, patent records.
[2] Patent landscape reports on kinase inhibitors and cancer therapies.
[3] Industry patent filings during 2010–2021.
[4] Competitive patent filings and legal status updates.
